Podcasts about abivax

  • 19PODCASTS
  • 32EPISODES
  • 25mAVG DURATION
  • 1MONTHLY NEW EPISODE
  • May 11, 2024LATEST
abivax

POPULARITY

20172018201920202021202220232024


Best podcasts about abivax

Latest podcast episodes about abivax

EUVC
David Bateman, Managing Partner at Claret Capital Partners on European venture debt in different market conditions | E310

EUVC

Play Episode Listen Later May 11, 2024 52:58


Today, we have with us David Bateman, Managing Partner at Claret Capital Partners a growth capital fund based in the United Kingdom.The venture capital fund has a total size of €297M with +€700M in AUM and focuses primarily on growth-stage and VC-backed deals with European companies that are typically post-Series B. As an investment thesis, they focus on technology and life science companies, and some of their most notable investments are in Abivax, Butternut Box, Holidu, and Veed.David has more than 20 years of experience in technology lending and financing. Prior to the buyout of Claret Capital from Harbert Management Corporation, he and Johan Kampe had co-founded Harbert European Growth Capital.Go to eu.vc for our core learnings and the full video interview

CEO Radio.TV
Abivax : Les Etats-Unis, le nouvel eldorado de la biotech | Marc de Garidel, CEO & Interim Chairman d'Abivax · Antabio

CEO Radio.TV

Play Episode Listen Later Feb 27, 2024 11:57


A travers ce podcast, Marc de Garidel nous livre son parcours professionnel en retraçant ses premiers pas dans le secteur pharmaceutique à son ascension au sein d'un grand groupe américain en tant que PDG. Il nous révèle qu'il a été confronté aux difficultés de financements du marché européen dans le secteur de la biotechnologie. Par ailleurs, il nous fait découvrir les joies de s'implanter aux Etats-Unis, où les investisseurs sont prêts à encourager ce domaine fleurissant. De plus, il nous explique les différentes phases du processus d'élaboration d'un médicament en évoquant la phase de recherche à la conception du produit final. Enfin, Marc de Garidel nous indique qu'après avoir inauguré Cincor Astrazeneca sur le marché, la prochaine étape pour lui est de faire d'Abivax un best-seller.

Flot.bio x Philip Hemme
Marc de Garidel, Abivax | How to make two billion

Flot.bio x Philip Hemme

Play Episode Listen Later Dec 4, 2023 71:33


Pharma minds
Marc de Garidel, CEO Abivax - Take risks to build something meaningful

Pharma minds

Play Episode Listen Later Nov 20, 2023 70:28


In the fascinating world of Pharma, a visionary and pragmatic man, @Marc de Garidel, stands out. His journey began in a down-to-earth family, setting the stage for an extraordinary adventure.

Pharma minds
[EXTRAIT] Marc de Garidel - CEO Abivax - "My 3 keys areas for success in biotech"

Pharma minds

Play Episode Listen Later Nov 19, 2023 1:49


Marc de Garidel is an emblematic figure in the pharmaceutical world.  Firstly, because he joined Amgen in its early days and contributed to the development of this biotech, almost 30 years ago. Secondly, because he led Ipsen to success in its commercial activities in the United States. Finally, for the past five years, he has been exploring the emerging world of biotechnology, leading to major developments and agreements: - Corvidia Therapeutics sold to Novo Nordisk in August 2020 - CinCor Pharma sold to AstraZeneca in February 2023  - Today, he is the CEO of Abivax In this extract, he explains the three key areas for choosing a promising biotech. In this episode, he looks back on his career and explains how he made his choices, but also his vision of today's pharma perspectives. - 1. Working together THE FARM & CO develops your visibility in Pharma using the strength of your therapeutic commitment, the uniqueness of your personality and the power of social networks. Build a presence aligned with your values. Ghostwriting, content creation & conversational tools. 2. My newsletter In my newsletter Pharma futurista, 2x/month, I jump into our society's evolutions and apply them to the future of Pharma. It's a short, 3-minute read on a subject that appeals to me. To receive it, you can subscribe here: https://nathalielahitte.substack.com/  or directly on my LinkedIn profile. 3. Get in touch with me!  If you like the podcast, the best way to tell me or share your thoughts is on the Apple podcast app. It really helps me out, so don't hesitate to share! If you'd like to ask me questions or follow my progress, you can do so on LinkedIn @nathalie lahitte .

Le Journal des Biotechs
Le Journal des biotechs : Marc de Garidel (Abivax)

Le Journal des Biotechs

Play Episode Listen Later Nov 17, 2023 16:09


Dans ce numéro hors série du Journal des biotechs, Marc de Garidel, PDG d'Abivax vient faire le point sur la situation de la biotech après l'introduction réussie au Nasdaq. Il détaille le déroulement de l'essai de Phase III dans la RCH et explique notamment le positionnement d'Abivax par rapport à ses concurrents directs.

Le Journal des Biotechs
Le Journal des biotechs : Frédéric Cren (Inventiva), Jamila El Bougrini (Invest Securities)

Le Journal des Biotechs

Play Episode Listen Later Nov 8, 2023 26:01


Dans ce numéro du Journal des biotechs, Jamila El Bougrini, analyste chez Invest Securities revient sur l'actualité récente ou à venir de Cellectis, Abivax et Genfit.L'entretien est consacré à Frédéric Cren, PDG d'Inventiva. Il revient sur l'accord récent conclu avec le groupe japonais Hepalys Pharma qui vient compléter son maillage asiatique. Il fait également le point sur les essais en cours avec Lanifibranor, l'état de la concurrence dans la Nash et la trésorerie de la société.

CCO Medical Specialties Podcast
Finding Your Friendtors: Mentors, Sponsors, and Allies

CCO Medical Specialties Podcast

Play Episode Listen Later Sep 25, 2023 28:53


In this podcast episode, Aline Charabaty, MD, AGAF, FACG, and Marla Dubinsky, MD, discuss how women in gastroenterology (GI) can find their “friendtors” and build a strong network of mentors, sponsors, and allies. Although there may be many barriers for women in the GI medicine specialty, these experienced leaders have useful tips to help emerging healthcare professionals avoid internalizing these challenges and strategically focus on accomplishing their goals.  Presenters:  Dr Aline Charabaty is an Assistant Professor of Medicine at Johns Hopkins School of Medicine, the Clinical Director of the IBD Centre at Johns Hopkins Sibley Memorial Hospital in Washington, DC, and the Co-Founder of Scrubs & Heels.  Aline Charabaty, MD, AGAF, FACG: consultant/advisor/speaker: AbbVie, Bristol Myers Squibb, Janssen, Lilly, Pfizer, Takeda.Dr Marla Dubinsky is a Professor of Pediatrics and Medicine at Mount Sinai in New York, Chief of Division of Pediatric GI and Nutrition at Mount Sinai Kravis Children's Hospital, and the Co-Director of the Susan and Leonard Feinstein IBD Clinical Centre. Dr Dubinsky is also the Director of the Marie and Barry Lipman IBD Preconception and Pregnancy Clinic. She is also an innovator and the Co-Founder of Trellus Health, providing personalized resilience coaching for people living with IBD. She received the Sherman Prize in 2022, which recognized her outstanding achievement in the field of IBD. In addition, she served as the Co-Chair for our inaugural Scrubs & Heels Leadership Summit in 2022.  Marla Dubinsky, MD: consultant/advisor/speaker: AbbVie, Abivax, AstraZeneca, Bristol Myers Squibb, Janssen, Lilly, Merck, Pfizer, Prometheus Biosciences, Takeda.Episode outline: Overview of barriers faced by women in GIImpact of failing to adequately address these barriersDefining the roles of mentors, sponsors, and alliesImportant qualities of mentors, sponsors, and alliesRole models vs peer mentorsOther program activities: Full Program: Equipped and Empowered: Thriving as Women in GIPodcast 2: Embracing Your Value: Tools and Strategies for Optimizing Professional Growth and DevelopmentPodcast 3: Being Your Full Self: Pursuing Work–Life BalanceClinicalThought: Expert Commentary on Thriving as Women in GIAfter selecting the “Continue to Post Test” button:To receive continuing education credit, submit your posttest answers no later than the expiration of this activity. Select 1 best answer for each question. When you have completed all the questions, press the "Continue" button at the bottom

Le Journal des Biotechs
Le journal des biotechs : Nicolas Poirier (OSE), Mohamed Kaabouni (Portzamparc)

Le Journal des Biotechs

Play Episode Listen Later May 18, 2023 28:53


Dans ce numéro du journal des biotechs Mohamed Kaabouni, analyste biotech chez Portzmparc, évoque les trois dossiers du moment: Abivax, Biophytis et Valneva.L'entretien est consacré à Nicolas Poirier, directeur général d'OSE Immunotherapeutics.Il revient sur la décision d'un commun accord d'arrêt l'accord de licence avec option signé fin 2016 avec Servier après les résultats négatifs de phase II de l'étude exploiratoire dans le syndrome de Sjögren.Il donne les rendez-vous importants de 2023 pour la biotech et fait le point sur les avancées dans les autres partenariats avec Boehringer Ingelheim et Veloxis.

BioBoss
#59 - Hartmut Ehrlich: CEO of Abivax

BioBoss

Play Episode Play 45 sec Highlight Listen Later Apr 22, 2023 50:11 Transcription Available


Hartmut Ehrlich,  CEO of Abivax, shares his thoughts with BioBoss host John Simboli about leadership in biopharma and how Abivax is working to develop treatments modulating the body's natural immune system to treat patients with chronic inflammatory diseases, viral infections and cancer.

Le Journal des Biotechs
Le journal des biotechs : Pascal Prigent (Genfit), Jamila El Bougrini (Invest Securities)

Le Journal des Biotechs

Play Episode Listen Later Apr 20, 2023 26:15


Dans ce numéro du journal des Biotechs, Jamila El Bougrini, analyste chez Invest Securities, passe en revue les dossiers chauds du moment : Abivax, avec l'arrivée de Marc de Garidel à la tête de la société en intérim, Lysogene, Transgene et les résultats présentés au congrès de l'AACR et enfin Nicox et l'autorisation de mise sur le marché obtenue en Chine par son partenaire local.L'entretien est consacré à Pascal Prigent. Outre les résultats 2022 récemment dévoilés, le directeur général de Genfit détaille les programmes en cours et surtout les rendez-vous importants qui attendent la biotech, à commencer par le premier d'entre eux : la publication des premiers résultats d'Elative, la phase 3 d'elafibranor dans la PBC, prévus d'ici la fin de ce 2e trimestre.

MICI Today
Alimentation et MICI

MICI Today

Play Episode Listen Later Nov 10, 2022 7:45


Existe-t-il un lien entre l'augmentation de l'incidence des MICI et l'alimentation ? Que penser du rôle des additifs alimentaires et des aliments ultra-transformés ? Que conseiller aux patients en pratique ? Quel est l'intérêt de la prise de compléments alimentaires ? Le Pr Xavier Hebuterne, chef du service de gastro-entérologie et nutrition au CHU de Nice, répond à vos questions.   Invité : Pr Xavier Hebuterne – CHU de Nice https://www.chu-nice.fr/offre-de-soins/digestif-addictologie-reanimation-chirurgicale-endocrinologie/appareil-digestif  Le Pr Hebuterne déclare des liens d'intérêt avec les laboratoires Abbvie, Abivax, Alphasigma, Arena, Gilead, Eli Lilly, Enterome, Fresenius-Kabi, Janssen, InDex Pharmaceuticals, Pfizer, Prometheus Biosciences, Sangamo, Takeda, Theravance, Boeringher Ingelheim, Celltrion, Fresenius-Kabi, Galapagos, Nestlé Health Sciences, Nordic Pharma, Amgen, MSD, Nutricia, Tillots, Viatris.   L'équipe :
 Comité éditorial : Pr Lucine Vuitton, Pr Guillaume Bouguen, Pr Mathurin Fumery, Dr Maeva Charkaoui, Dr Mathieu Uzzan, Justine Amaro, Charlotte Mailhat, Justine Pollet Animation :  Pyramidale Communication Production : Pyramidale Communication Soutien institutionnel : Pfizer   Crédits : Pyramidale Communication, Sonacom

Der Anleger Podcast
90. Roadshow-Podcast Biotech, mit Prof. Dr. Ehrlich, CEO Abivax

Der Anleger Podcast

Play Episode Listen Later Dec 4, 2021 15:17


Lange galten vor allem Pharmakonzerne als unangefochtene Kämpfer gegen Krankheiten. Doch mehr und mehr rückte mit neuartigen Forschungsansätzen die Biotech-Branche in den Vordergrund. Daher haben wir für Euch eine Art Roadshow-Podcast auf die Beine gestellt, in welchem sich verschiedene Biotech-Unternehmen vorstellen. Starten möchten wir mit Herrn Prof. Dr. Ehrlich, er ist CEO des französischen Biotech-Unternehmen Abivax. Schreibt uns: podcast@effecten-spiegel.de www.effecten-spiegel.com

Good Morning Business
Docteur Philippe Pouletty, président d'Abivax - 26/05

Good Morning Business

Play Episode Listen Later May 26, 2021 5:28


Docteur Philippe Pouletty, président d'Abivax et cofondateur de Truffle Capital, était l'invité de Christophe Jakubyszyn dans Good Morning Business, ce mercredi. Ils sont revenus sur le bon résultat de l'ABX464, un traitement contre la rectocolite hémorragique, une maladie inflammatoire de l'intestin, sur BFM Business. Retrouvez l'émission du lundi au vendredi et réécoutez la en podcast.

business ils succes entreprises docteur bfm business abivax good morning business christophe jakubyszyn sandragandoin christophejakubyszyn
Le Journal des Biotechs
Le JDB : Marc Delcourt (Global Bioenergies) & Christophe Dombu (Portzamparc)

Le Journal des Biotechs

Play Episode Listen Later May 7, 2021 31:24


Dans ce numéro du journal des biotechs, Christophe Dombu, analyste chez Portzamparc revient sur les financements en cours dans le secteur et détaille l'actualité de trois dossiers : Abivax, OSE Immuno et Valneva. L'entretien est consacré à Marc Delcourt, directeur général de Global Bioenergies. La biotech spécialisée dans la production d'isobutène d'origine végétale s'engage dans une diversifications audacieuse en lançant sa propre marque de cosmétiques.

Web Tv Bourse Economie Entreprises's posts
Didier Blondel Directeur Financier Abivax : “On rentre dans le coeur de la stratégie d’Abivax avec le ABX464” : 8e #ConfPortzamparc dédiée aux #valeursMidAndSmall

Web Tv Bourse Economie Entreprises's posts

Play Episode Listen Later Mar 30, 2021 14:08


La 8e #ConfPortzamparc dédiée aux #valeursMidAndSmall se tient du 29 mars au 1er avril en format 100% digital. 55 émetteurs iront à la rencontre des investisseurs. LA BOURSE ET LA VIE TV est partenaire de l’évènement et Didier Testot son fondateur a interrogé plusieurs entreprises sur leurs stratégies et perspectives. Abivax SA (Euronext Paris : FR0012333284 – ABVX) est une société de biotechnologie au stade clinique développant des nouveaux médicaments modulant le système immunitaire afin de traiter les maladies inflammatoires, le cancer et les maladies virales. La société a annoncé début mars qu’elle “arrêtait l’étude miR-AGE de phase 2b/3 chez les patients Covid-19 à risque élevé conformément à la recommandation du Data Safety and Monitoring Board (DSMB) pour raison de manque d’efficacité“. Cette annonce suscita des ventes du titre en Bourse. Selon Abivax, “l’étude internationale miR-AGE de phase 2b/3 (ABX464-401) avait d’ores et déjà recruté 500 patients Covid-19 à risque élevé, sur les 1 034 prévus et avait été désignée « Priorité Nationale de Recherche » par le gouvernement français en décembre 2020. L’essai clinique à la méthodologie rigoureuse, conduit de manière randomisée, en double aveugle et contrôlé contre placebo évaluait la capacité d’ABX464 de prévenir la progression vers la forme grave de la maladie chez les patients. La recommandation du DSMB est basée sur une analyse intermédiaire évaluant les données de 305 patients Covid-19 à risque élevé qui ont terminé le traitement. La comparaison des données générées chez les patients traités avec ABX464 versus le groupe placebo n’a pas démontré de différence sur le taux de progression vers une maladie sévère entre le groupe placebo et le groupe ABX464. Par ailleurs, ABX464 s’est relevé sûr et bien toléré chez ces patients Covid-19 à risque élevé.” Retour sur les dernières actualités de l’entreprise, sa stratégie avec le ABX464 et les perspectives. Didier Blondel Directeur Financier Abivax est mon invité. Vidéos Abivax déjà diffusées sur la Web TV : Biotech .pf-button.pf-button-excerpt { display: none; }L’article Didier Blondel Directeur Financier Abivax : “On rentre dans le coeur de la stratégie d’Abivax avec le ABX464” : 8e #ConfPortzamparc dédiée aux #valeursMidAndSmall est apparu en premier sur La Bourse et la Vie TV L'information éco à valeur ajoutée.

Le Journal des Biotechs
Le JDB : Laurent Lévy (Nanobiotix) & Frédéric Gomez (Pharmium Securities)

Le Journal des Biotechs

Play Episode Listen Later Mar 25, 2021 34:01


Dans cet épisode du journal des biotechs, l'oeil aiguisé de Frédéric Gomez, analyste chez Pharmium Securities se pose sur les résultats d'études attendus d'Abivax et Gensight et sur les autorisations de mise sur le marché en cours pour DBV, Gensight et Advicenne. abiL'entretien est consacré à Laurent Lévy, président du directoire de Nanobiotix. Après l'introduction réussie sur le Nasdaq, il revient sur les priorités stratégiques du spécialiste des nano particules

Good Morning Business
Philippe Pouletty, Président d'Abivax et cofondateur de Truffle Capital - 23/12

Good Morning Business

Play Episode Listen Later Dec 23, 2020 7:23


Good Morning Business
Philippe Pouletty, Président d'Abivax et cofondateur de Truffle Capital - 23/12

Good Morning Business

Play Episode Listen Later Dec 23, 2020 7:23


Good Morning Business
Philippe Pouletty, Président d'Abivax et cofondateur de Truffle Capital - 23/12

Good Morning Business

Play Episode Listen Later Dec 23, 2020 7:23


trialsitenews's podcast
Hartmut Ehrlich and Philippe Pouletty discuss Abivax Clinical Programs Involving Covid-19 and more.

trialsitenews's podcast

Play Episode Listen Later Dec 9, 2020 33:24


Hartmut Ehrlich and Philippe Pouletty discuss Abivax Pipeline of Clinical Programs involving Covid-19, Ulcerative Colitis, Crohn's Disease and more. https://www.abivax.com/pipeline/   - #COVID-19 https://www.abivax.com/pipeline/abx464-for-covid-19/ Ongoing Phase 2b/3 trial with ABX464 in Covid-19 (miR-AGE trial), the unique properties of the lead candidate (antiviral, anti-inflammatory, tissue repair) to treat elderly and high-risk Covid-19 patients, the rial is ongoing in Europe and Brazil (Mexico, Peru and Chile to follow shortly) -#Cancer https://www.abivax.com/pipeline/abx196/ ABX196 has been developed as a synthetic agonist of iNKT cells from a proprietary platform technology that identifies agonists of these types of cells that demonstrate immune enhancing effects in cancer models. Preclinical data showed that ABX196 enhanced anti-tumoral activity when used alone and in combination with anti-PD1 antibodies or doxorubicin. - Ulcerative Colitis https://www.abivax.com/pipeline/abx464-ibd-uc/ ABX464 in Inflammatory Bowel Diseases (Abivax development priority), excellent two-year efficacy and safety data for ABX464 ulcerative colitis Phase 2a maintenance study and ongoing ulcerative colitis Phase 2b trial in 15 countries, the US and Canada - Crohn's disease https://www.abivax.com/pipeline/abx464-for-crohns-disease/ Planned pivotal Phase 2b/3 trial with ABX464 in Crohn's disease (FPI Q1 2021) and ngoing clinical trial with ABX464 in rheumatoid arthritis in 5 European countries - HC Ongoing clinical trial with second molecule, ABX196, in patients with hepatocellular carcinoma in the US

The Bio Report
Modulating RNA to Quell Disease

The Bio Report

Play Episode Listen Later Nov 26, 2020 26:59


Traditional efforts to treat autoimmune conditions have focused on inhibiting proteins involved in the immune response. Abivax is developing therapies that modulate RNA to enhance the body's natural machinery to disrupt the production of cytokines, the proteins that signal the immune system to mount an attack in the first place. The company's approach to modulating RNA may not only have utility in autoimmune conditions like inflammatory bowel disease, but in other indications including infectious disease and cancer. We spoke to Hartmut Ehrlich, CEO of Abivax, about the company's lead therapeutic, how it works, and why the approach can have implications in a broad range of diseases.

Spectrum | Deutsche Welle
A miracle from France?

Spectrum | Deutsche Welle

Play Episode Listen Later May 27, 2020 4:10


If you were told there’s a drug that can stop COVID-19, treat symptoms and heal tissue, would you believe it? Listen to DW's science podcast for a different angle on the coronavirus — five minutes every day from Germany.

Empowered Patient Podcast
Novel Anti-Inflammatory Therapeutic Agent Showing Promise for Ulcerative Colitis with Dr. Hartmut Ehrlich Abivax

Empowered Patient Podcast

Play Episode Listen Later Mar 24, 2020 19:12


Dr. Hartmut Ehrlich, CEO, Abivax  gives an update of the French biotech's phase-2b clinical trial drug candidate ABX464 which has shown impressive results.  Dr. Ehrlich discusses how this revolutionary small molecule for oral administration has shown strong anti-inflammatory effects to solve the unmet needs of patients with inflammatory conditions like ulcerative colitis, Crohn's disease, and arthritis by using the body's own immune system to fight the diseases. @abivax #abivax  #inflammation #IBD #rheum Abivax.com Download the transcript here

Empowered Patient Podcast
Novel Anti-Inflammatory Therapeutic Agent Showing Promise for Ulcerative Colitis with Dr. Hartmut Ehrlich Abivax TRANSCRIPT

Empowered Patient Podcast

Play Episode Listen Later Mar 24, 2020


Dr. Hartmut Ehrlich, CEO, Abivax  gives an update of the French biotech's phase-2b clinical trial drug candidate ABX464 which has shown impressive results.  Dr. Ehrlich discusses how this revolutionary small molecule for oral administration has shown strong anti-inflammatory effects to solve the unmet needs of patients with inflammatory conditions like ulcerative colitis, Crohn's disease, and arthritis by using the body's own immune system to fight the diseases. @abivax #abivax  #inflammation #IBD #rheum Abivax.com Listen to the podcast here  

Empowered Patient Podcast
Unique Therapy for Multiple Inflammatory Diseases with Dr. Jean-Marc Steens Abivax

Empowered Patient Podcast

Play Episode Listen Later Jun 4, 2019 16:45


Dr. Jean-Marc Steens, Chief Medical Officer, Abivax reports on clinical results that continue to show advances in the chronic treatment and maintenance of moderate to severe ulcerative colitis using a new small molecule ABX464 in an oral treatment and potential applications for other inflammatory and neurological diseases.  Jean-Marc also explains how another molecule ABX196 is being tested to determine if it might increase the outcome of treatments for hepatocellular carcinoma, the most common liver cancer, in conjunction with Opdivo a checkpoint inhibitor that is being developed with Scripps Research, University of Chicago and BYU.  #ulcerativecolitis Abivax    

Empowered Patient Podcast
Unique Therapy for Multiple Inflammatory Diseases with Dr. Jean-Marc Steens Abivax--TRANSCRIPT

Empowered Patient Podcast

Play Episode Listen Later Jun 4, 2019


Dr. Jean-Marc Steens, Chief Medical Officer, Abivax reports on clinical results that continue to show advances in the chronic treatment and maintenance of moderate to severe ulcerative colitis using a new small molecule ABX464 in an oral treatment and potential applications for other inflammatory and neurological diseases.  Jean-Marc also explains how another molecule ABX196 is being tested to determine if it might increase the outcome of treatments for hepatocellular carcinoma, the most common liver cancer, in conjunction with Opdivo a checkpoint inhibitor that is being developed with Scripps Research, University of Chicago and BYU.  Read the transcript and listen to the podcast.

Empowered Patient Podcast
Drug Moves From Antiviral to Treating Inflammatory Diseases with Dr. Hartmut Ehrlich Abivax

Empowered Patient Podcast

Play Episode Listen Later Apr 8, 2019 17:04


Dr. Hartmut Ehrlich, CEO of Abivax discusses the exciting new progress that this French biotechnology company has observed in clinical trials of their most advanced clinical drug candidate, ABX464.  Originally designed to treat HIV by reducing the viral reservoir, Abivax determined the molecule could also be a game-changing treatment in a variety of inflammatory conditions like ulcerative colitis, Crohn's disease and arthritis. #Abivax #ABVX #HIV #UlcerativeColitis #UC #inflammation #IBD Abivax.com

TechNation Radio Podcast
Episode 18-02 Virtual Reality – Dawn of the New Everything

TechNation Radio Podcast

Play Episode Listen Later Jan 9, 2018 59:00


On this week's Tech Nation, Jaron Lanier talks about “Dawn of the New Everything: Encounters with Reality and Virtual Reality”. Then on Tech Nation Health, Dr. Hartmut Ehrlich, the CEO opf Abivax, describes their efforts to keep HIV undetectable for longer and longer periods, and Chief Correspondent Dr. Daniel Kraft explores the future of going to the doctor.

TechNation Health Podcast
Episode 18-02 Efforts to keep HIV undetectable for longer periods

TechNation Health Podcast

Play Episode Listen Later Jan 9, 2018 19:03


On this week’s Tech Nation Health, Dr. Hartmut Ehrlich, the CEO of Abivax, describes their efforts to keep HIV undetectable for longer and longer periods, and Chief Correspondent Dr. Daniel Kraft explores the future of going to the doctor.

ceo effort longer hiv periods undetectable daniel kraft abivax tech nation health chief correspondent dr
BioTech Nation Radio Podcast
Episode 18-02 Virtual Reality – Dawn of the New Everything

BioTech Nation Radio Podcast

Play Episode Listen Later Jan 9, 2018 59:00


On this week’s BioTech Nation, Jaron Lanier talks about “Dawn of the New Everything: Encounters with Reality and Virtual Reality”. Then on Tech Nation Health, Dr. Hartmut Ehrlich, the CEO opf Abivax, describes their efforts to keep HIV undetectable for longer and longer periods, and Chief Correspondent Dr. Daniel Kraft explores the future of going to the doctor.

ceo reality hiv virtual reality jaron lanier new everything daniel kraft abivax tech nation health chief correspondent dr
FirstWord Pharmaceutical News
FirstWord Pharmaceutical News for Tuesday, May 2 2017

FirstWord Pharmaceutical News

Play Episode Listen Later May 2, 2017 1:51